SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; et al. Mikropoulos, C; Selkirk, CGH; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MG; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, AT; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer, 118 (2). pp. 266-276. ISSN 1532-1827 https://doi.org/10.1038/bjc.2017.429
SGUL Authors: Snape, Katie Mairwen Greenwood

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

Download (367kB) | Preview

Abstract

BACKGROUND: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. METHODS: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV. RESULTS: 1634 participants had ⩾3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml-l, PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P=0.031) and BRCA2 status and PSAV (P=0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. CONCLUSIONS: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.

Item Type: Article
Additional Information: © The Author(s) named above This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
Keywords: Oncology & Carcinogenesis, 1112 Oncology And Carcinogenesis
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: Br J Cancer
ISSN: 1532-1827
Language: eng
Dates:
DateEvent
4 January 2018Published
6 November 2017Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-Share Alike 4.0
Projects:
Project IDFunderFunder ID
C5047/A21332Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
C5047/A13232Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
C5047/A17528Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
PubMed ID: 29301143
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109592
Publisher's version: https://doi.org/10.1038/bjc.2017.429

Actions (login required)

Edit Item Edit Item